CollPlant Appoints Roger J. Pomerantz as Chairman of the Board of Directors

Roger J. Pomerantz, with all his expertise and experience, serves as the Chairman of the Board of Directors, at CollPlant.  

FREMONT, CA: A regenerative and aesthetic medicine company, CollPlant has appointed Roger J. Pomerantz, M.D., F.A.C.P. as the Chairman of the Board of Directors. Currently, he is ContraFect's President, Chief Executive Officer, and Chairman of the Board of Directors. Dr. Pomerantz has many years of experience, and in addition to serving ContraFect, he also serves on the boards of VerImmune and Intec Pharma. Serving Aridis Pharmaceuticals as the Chairman of the Scientific Advisory Board, he was a Venture Partner at Flagship Pioneering from 2014 through 2019.

"Dr. Pomerantz's extensive knowledge of the life science industry as a clinician, senior executive and board member is exactly what we need as we bolster our strategic partnerships and clinical development efforts for our recombinant human collagen (rhCollagen) technology platform," says Yehiel Tal, CollPlant Chief Executive Officer. "Roger is an excellent addition to our team and will play an integral role in our mission to provide optimal treatment options for patients through ground-breaking solutions in the field of regenerative and aesthetic medicine."

Dr. Pomerantz served as the President, Chief Executive Officer, and Chairman of the Board of Seres Therapeutics previously, where he still serves as an advisor. Also, he was the Senior Vice President, Worldwide Head of Licensing & Acquisition at Merck & Co., Inc. Dr. Pomerantz was the Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. He has experience as a Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals. With his expertise and experience, he is sure to implement new ideas for the growth of CollPlant.

CollPlant is a regenerative and aesthetic medicine organization advancing innovative technologies and products for tissue regeneration and organ manufacturing. The company's plant-based technology is an innovative commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen) that is identical to the collagen produced by the human body. CollPlant's mission is to deliver ground-breaking products for regenerative medicine that provide optimal treatment options for patients.